September 22, 2009
All three components of sexual health -- desire, function, and satisfaction -- may be negatively impacted for men taking standard therapy for chronic hepatitis C, new research shows.
"Men planning to receive peginterferon and ribavirin should be counseled about the possibility of a decline in sexual health during treatment and receive adequate support if these side effects occur," according to lead author Dr. Lorna M. Dove of New York Presbyterian Medical Center and colleagues.
The subjects of the current study were 260 men taking the combination treatment for chronic hepatitis C. They completed self-administered questionnaires before, during, and after treatment.
When therapy ended, at 24 or 48 weeks, 38-48 percent of the men said their "overall sexual function was worse than before treatment." Caucasian-American men reported more impairment than African-American men.
"By 24 weeks after treatment, sexual desire and satisfaction improved and were comparable to baseline levels," the authors wrote. "However, among men who received 48 weeks of therapy, the estimated percentage of men reporting post-treatment erectile or ejaculatory problems remained higher than baseline, although persistent erectile impairment was limited to Caucasian-American patients."
"Sexual impairment is common among men with chronic hepatitis C undergoing therapy with pegylated interferon and ribarvirin and should be considered as a potential side effect of antiviral therapy," the authors concluded.
The report, "Decline in Male Sexual Desire, Function and Satisfaction During and After Antiviral Therapy for Chronic Hepatitis C," was published in Gastroenterology (2009;137(3):873-884).
09.16.09; Reuters Health
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|No Increased Risk of Liver Cancer After Hepatitis C Treatment With Direct-Acting Antivirals|
|This Week in HIV Research: Another Person Possibly Cured of HIV; and Long-Acting Rilpivirine Suppresses HIV in Rectal Tissue|
|This Week in HIV Research: HIV-Related Inflammation May Be Irreversible; and Genetically Engineered T-Cells Resist HIV|
|How Close Are We to a Cure for HIV? A Q&A With HIV Cure Scientific Superstars|
|Dolutegravir and the Central Nervous System: A Top HIV Clinical Development of 2016|